Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Litorina V in connection with the acquisition of Sushi Yama
Mandate

Vinge advises Litorina V in connection with the acquisition of Sushi Yama

August 11, 2020 Employment and Benefits Banking and Finance Commercial Agreements Intellectual Property M&A Environmental Law Real Estate and Construction

Sushi Yama is a leading sushi restaurant chain with over 45 restaurants in Sweden.

Sushi Yama was the first chain in the Nordics to certify all its restaurants to serve ASC and MSC certified products to its customers. Thanks to the partnership, Sushi Yama can now accelerate its expansion in Sweden and internationally.

Vinge’s team consisted of Jonas Johansson together with, among others, Carl Sander, Christina Odengran and Ellinor Wargenbrant (M&A), Karolina Cohrs and Frida Ställborn (Real estate), Cornelia Medrek and Olof Löfvenberg (Environment), Victoria Ribbnäs and Axel Jansson (Banking and Finance), Ebba Svenburg (Employment), Agnes Perbo and Lova Unge (Commercial Agreements), Ilze Lukins (IP), Johan Wahlbom (Competition law) and VDR-specialist Viktoria Owetz Leyva.

Related

Vinge advises Vinci Concessions SAS and its subsidiary SunMind SAS in connection with its acquisition of Helios Nordic Energy AB from Magnora ASA, management and early investors

 Helios Nordic Energy specialises in developing solar farms and batteries to store energy until they become Ready to Build in the Nordics and Baltics.
May 30, 2024

Vinge has advised Samhällsbyggnadsbolaget i Norden AB (“SBB”) in connection with SBB establishing a new joint venture with Castlelake, LP (“Castlelake”).
May 28, 2024

Vinge advises Calliditas Therapeutics in connection with Asahi Kasei Corporation’s public takeover offer

 On 28 May 2024, Asahi Kasei Corporation announced a public takeover offer to the shareholders and holders of American Depositary Shares in Calliditas Therapeutics AB (publ) (”Calliditas Therapeutics”) to acquire all shares and American Depositary Shares (each representing two shares) in Calliditas Therapeutics.
May 28, 2024